A group of advisers to the Food and Drug Administration will meet Tuesday to discuss one of the most important questions since coronavirus vaccines first became available last year: whether to make them available to young children.
Their recommendation could pave the way for the roughly 28 million Americans between 5 and 11 years old to receive Pfizer and BioNTech’s vaccine, a potential turning point in the pandemic. A positive outcome is anticipated by the Biden administration, which, as with booster shots earlier this summer, detailed its rollout plans before drug regulators made their decision.
